|
See related Integrilin information |
|
|
|
Manufacturer |
MSD |
|
Distributor |
Hong Kong: DKSH/Macau: Four Star |
|
Contents |
Eptifibatide |
|
Indications |
Acute coronary syndrome (unstable angina or non-Q-wave MI). Percutaneous coronary intervention (PCI) including those undergoing intracoronary stenting. |
|
Dosage |
Acute coronary syndrome w/ serum creatinine <2 mg/dL IV bolus of 180 mcg/kg as soon as possible after diagnosis, followed by a continuous infusion of 2 mcg/kg/min up to 72 hr or until discharge, If PCI is performed during Integrilin therapy, the infusion should be continued for up to 18-24 hr after the procedure or until discharge, allowing 96 hr of therapy. PCI w/ serum creatinine <2 mg/dL IV bolus of 180 mcg/kg immediately before initiation of PCI followed by a continuous infusion of 2 mcg/kg/min & a 2nd 180 mcg/kg bolus 10 min after the 1st bolus, continue infusion for up to 18-24 hr or until discharge. |
|
Contraindications |
GI bleeding; gross GUT bleeding or other active normal bleeding w/in the previous 30 days of treatment; hepatic impairment; history of bleeding diathesis; severe HTN not adequately controlled on antihypertensive therapy; major surgery w/in the preceding 6 wk; history of stroke w/in 30 days or any history of hemorrhagic stroke; current or planned administration of another parenteral glycoprotein IIb/IIIa inhibitor; thrombocytopenia (<100,000 cells/mm3); prothrombin time >1.2 times control or INR ≥2; renal dialysis. |
|
Special Precautions |
If severe bleeding occurs, discontinue therapy. Hepatic & renal impairment. Pregnancy & lactation. |
|
Adverse Drug Reactions |
Bleeding, intracranial hemorrhage, stroke, thrombocytopenia, allergic reactions.
View ADR Monitoring Form |
|
Drug Interactions |
Increased risk of bleeding w/ heparin, other anticoagulants, antiplatelet & thrombolytic agents.
View more drug interactions with Integrilin |
|
Pregnancy Category (US FDA) |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
|
ATC Classification |
B01AC16 - eptifibatide ; Belongs to the class of platelet aggregation inhibitors excluding heparin. Used in the treatment of thrombosis. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Integrilin infusion |
|
Integrilin 75 mg/100 mL x 1's |
|
|
Integrilin injection |
|
Integrilin 20 mg/10 mL x 1's |
|
|
|
Manufacturer: |
MSD |
|
Distributor: |
Hong Kong: DKSH
Macau: Four Star |
|
|
|
|
